Latest period
−$13.90M
YoY change
-31.5%
5Y CAGR
—
Peak year (2021)
$118.61M
Latest annual
−$38.33M
Operating Cash Flow history chart for Ovid Therapeutics (OVID) from 2014 to 2025
Latest: −$38.33M
Operating Cash Flow growth chart for Ovid Therapeutics (OVID) from 2014 to 2025
Latest: -31.5%
Operating Cash Flow history table for Ovid Therapeutics (OVID) from 2014 to 2025
| 2025 | −$38.33M | -31.5% | +$17.62M | ||
| 2024 | −$55.96M | +22.2% | −$10.18M | ||
| 2023 | −$45.78M | -17.1% | +$9.45M | ||
| 2022 | −$55.23M | -146.6% | −$173.84M | ||
| 2021 | $118.61M | -329.9% | +$170.20M | ||
| 2020 | −$51.58M | +1.0% | −$493.29K | ||
| 2019 | −$51.09M | +12.1% | −$5.53M | ||
| 2018 | −$45.56M | +44.8% | −$14.09M | ||
| 2017 | −$31.47M | +76.8% | −$13.67M | ||
| 2016 | −$17.80M | +224.5% | −$12.32M | ||
| 2015 | −$5.49M | +1999.5% | −$5.22M | ||
| 2014 | −$261.28K | — | — |
- 2025−$38.33M-31.5%
- 2024−$55.96M+22.2%
- 2023−$45.78M-17.1%
- 2022−$55.23M-146.6%
- 2021$118.61M-329.9%
- 2020−$51.58M+1.0%
- 2019−$51.09M+12.1%
- 2018−$45.56M+44.8%
- 2017−$31.47M+76.8%
- 2016−$17.80M+224.5%
- 2015−$5.49M+1999.5%
- 2014−$261.28K—
Operating Cash Flow values are taken from Ovid Therapeutics's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Cash Flow at Ovid Therapeutics (OVID)
Operating Cash Flow for Ovid Therapeutics (OVID): headline value −$13.90M · YoY -31.5%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, Ovid Therapeutics (OVID) operating cash flow totalled −$38.33M – plunged 31.5% year-over-year.
Ovid Therapeutics operating cash flow plunged from $118.61M in 2021 to −$38.33M in 2025, a 132.3% drawdown.
Across the available history, operating cash flow reached its high of $118.61M in 2021 and its low of −$55.96M in 2024.
Ovid Therapeutics Operating Cash Flow by Year
Ovid Therapeutics Operating Cash Flow 2025: −$38.33M
Ovid Therapeutics posted operating cash flow of −$38.33M in 2025, plunged 31.5% below 2024.
Ovid Therapeutics Operating Cash Flow 2024: −$55.96M
In 2024, Ovid Therapeutics reported operating cash flow of −$55.96M, grew 22.2% from 2023. This figure represents the lowest annual value in the available history.
Ovid Therapeutics Operating Cash Flow 2023: −$45.78M
Ovid Therapeutics operating cash flow in 2023 was −$45.78M, declined 17.1% below 2022.
Ovid Therapeutics Operating Cash Flow 2022: −$55.23M
2022's operating cash flow for Ovid Therapeutics came in at −$55.23M, plunged 146.6% below 2021.
Ovid Therapeutics Operating Cash Flow 2021: $118.61M
Ovid Therapeutics operating cash flow in 2021 was $118.61M.
See more financial history for Ovid Therapeutics (OVID).
Sector peers by Operating Cash Flow
Healthcare peers of Ovid Therapeutics (OVID), ranked by their latest operating cash flow
| $24.53B | |
| $19.70B | |
| $19.03B | |
| $18.56B | |
| $16.81B | |
| $16.47B | |
| $14.57B | |
| $9.96B |
- $24.53B
- $19.70B
- $19.03B
- $18.56B
- $16.81B
- $16.47B
- $14.57B
- $9.96B
Frequently asked questions
Ovid Therapeutics (OVID) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation